Program
arcotatug tavatecan
Also written as “IBI343”, “IBI343,Gemcitabine, Albumin-bound Paclitaxel” and “IBI343,sintilimab,oxaliplatin,S-1”.
Its studies are mostly in Pancreatic Neoplasms, led by Innovent Biologics.
Furthest: phase 3, since Jan 25, 20245 company-led studies, 5 open or runningNext primary completion: Dec 30, 2026 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 55 open or running | phase 3since Jan 25, 2024 | Jul 11, 2022 | Dec 30, 2026phase 3 · NCT06238843 |
Also a collaborator on its studies: TigerMed.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 11, 2022First study: phase 1 study in Locally Advanced Unresectable or Metastatic Solid TumorsFirst studyNCT05458219 · 470 planned · United States, Australia, China
- Jan 25, 2024Phase 3 study in Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNCT06238843 · 464 enrolled · China, Japan
- Jun 26, 2025Phase 3 study in Pancreatic NeoplasmsNCT07066098 · 201 planned · China
- Mar 16, 20262 phase 2 studies in CLDN18.2 PositiveNCT07483567, NCT07483554
Ahead
- Dec 30, 2026Primary completion: phase 3 study in Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaNCT06238843
- Jun 30, 2027Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07066098
- Jun 30, 2027Primary completion: phase 1 study in Locally Advanced Unresectable or Metastatic Solid TumorsNCT05458219
- Mar 31, 2028Primary completion: phase 2 study in CLDN18.2 PositiveNCT07483554
TargetBeta
CLDN18 →read by rule
“An antibody-drug conjugate (ADC) composed of arcotatug, a Fc-silenced humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), ”NCIt, by rule
Other programs on CLDN18
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zolbetuximabrule | Astellas Pharma | phase 4 | 12 |
| sonesitatug vedotin | AstraZeneca | phase 3 | 7 |
| garetatug rezetecan | Jiangsu HengRui Medicine | phase 3 | 7 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905rule | Qilu Pharmaceutical | phase 3 | 6 |
| tecotabart vedotin | Sino Biopharmaceutical | phase 3 | 6 |
| terallethrinrule | FutureGen Biopharmaceutical (Beijing) | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1 | biokin-shanghai-biopharmaceutical-co-ltd | phase 3 | 3 |
| emaretamigrule | Astellas Pharma | phase 3 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200rule | Sichuan Kelun Pharmaceutical | phase 2 | 3 |
| Anti-Claudin 18.2 Antibody-drug Conjugate ASP546Crule | Astellas Pharma | phase 2 | 2 |
| givastomigrule | i-mab-biopharma-us-limited | phase 2 | 2 |
| Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863 | AstraZeneca | phase 2 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07483567CLDN18.2 Positive · China | 2 | Recruiting | Jun 30, 2030 | 90 |
| NCT07483554CLDN18.2 Positive · China | 2 | Recruiting | Mar 31, 2028 | 389 |
| NCT07066098Pancreatic Neoplasms · China | 3 | Recruiting | Jun 30, 2027 | 201 |
| NCT06238843Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma · China, Japan | 3 | Active, not recruiting | Dec 30, 2026 | 464 |
| NCT05458219Locally Advanced Unresectable or Metastatic Solid Tumors · United States, Australia, China | 1 | Recruiting | Jun 30, 2027 | 470 |
How it is read
Names in the registry
- “IBI343”, 4 entries
- “IBI343,Gemcitabine, Albumin-bound Paclitaxel”, 1 entry
- “IBI343,sintilimab,oxaliplatin,S-1”, 1 entry
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.